Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DSGN NASDAQ:NBTX NASDAQ:NEOS NASDAQ:OMER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$4.04-3.1%$3.79$2.60▼$7.77$236.73M1.56178,862 shs65,012 shsNBTXNanobiotix$5.36+0.3%$4.33$2.76▼$6.00$251.69M0.4115,481 shs3,768 shsNEOSNeos Therapeutics$1.15$1.06$0.45▼$1.68$57.22M1.57.44 million shs15.01 million shsOMEROmeros$3.46+2.4%$3.73$2.95▼$13.60$198.04M2.16735,007 shs784,232 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics+14.56%+13.32%+6.65%+49.46%+19.14%NBTXNanobiotix-1.66%+8.87%+13.98%+66.88%+1.62%NEOSNeos Therapeutics0.00%0.00%0.00%0.00%0.00%OMEROmeros+7.99%+9.39%-10.34%-42.32%-13.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDSGNDesign Therapeutics0.4001 of 5 stars1.01.00.00.00.62.50.6NBTXNanobiotix2.2741 of 5 stars3.33.00.00.02.90.00.6NEOSNeos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOMEROmeros3.3055 of 5 stars3.40.00.04.40.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDSGNDesign Therapeutics 2.00Hold$4.00-0.99% DownsideNBTXNanobiotix 2.50Moderate Buy$8.0049.39% UpsideNEOSNeos Therapeutics 0.00N/AN/AN/AOMEROmeros 2.83Moderate Buy$18.00420.23% UpsideCurrent Analyst Ratings BreakdownLatest NEOS, DSGN, OMER, and NBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.006/27/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/10/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/16/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/7/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/11/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/ANBTXNanobiotix$39.18M6.44N/AN/A($1.51) per share-3.55NEOSNeos Therapeutics$64.65M0.89N/AN/A($0.12) per share-9.58OMEROmerosN/AN/AN/AN/A($3.15) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDSGNDesign Therapeutics-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/16/2025 (Estimated)NEOSNeos Therapeutics-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/AOMEROmeros-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)Latest NEOS, DSGN, OMER, and NBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025OMEROmeros-$0.46N/AN/AN/AN/AN/A8/4/2025Q1 2025DSGNDesign Therapeutics-$0.32N/AN/AN/AN/AN/A5/15/2025Q1 2025OMEROmeros-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDSGNDesign TherapeuticsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ANEOSNeos TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDSGNDesign TherapeuticsN/A28.3728.37NBTXNanobiotixN/A1.041.04NEOSNeos TherapeuticsN/A0.660.53OMEROmerosN/A1.161.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDSGNDesign Therapeutics56.64%NBTXNanobiotix38.81%NEOSNeos Therapeutics33.13%OMEROmeros48.79%Insider OwnershipCompanyInsider OwnershipDSGNDesign Therapeutics31.20%NBTXNanobiotix3.45%NEOSNeos Therapeutics3.80%OMEROmeros12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDSGNDesign Therapeutics4056.77 million39.06 millionOptionableNBTXNanobiotix10047.13 million45.51 millionNot OptionableNEOSNeos Therapeutics21349.76 millionN/AOptionableOMEROmeros21058.59 million51.04 millionOptionableNEOS, DSGN, OMER, and NBTX HeadlinesRecent News About These CompaniesOmeros (NASDAQ:OMER) Receives Buy Rating from D. Boral CapitalJune 30, 2025 | marketbeat.comOmeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival BoostJune 30, 2025 | msn.comOmeros (NASDAQ:OMER) Downgraded to "Sell" Rating by Wall Street ZenJune 27, 2025 | marketbeat.comOmeros (OMER) Eyes European Approval for Key Drug Narsoplimab | OMER Stock NewsJune 27, 2025 | gurufocus.comOmeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMAJune 27, 2025 | businesswire.comOmeros Co. (NASDAQ:OMER) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 16, 2025 | marketbeat.com‘Hundreds’ of documents to review in Omeros money laundering case, defence lawyer tells courtJune 12, 2025 | couriermail.com.auCWhat is HC Wainwright's Forecast for Omeros FY2025 Earnings?June 12, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Omeros (OMER) with Buy RecommendationJune 12, 2025 | msn.comOmeros Stock Short Interest Report | NASDAQ:OMER | BenzingaJune 11, 2025 | benzinga.comHC Wainwright Predicts Omeros' Q2 Earnings (NASDAQ:OMER)June 11, 2025 | marketbeat.comOmeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA DecisionJune 10, 2025 | benzinga.comBrokers Set Expectations for Omeros FY2026 EarningsJune 10, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Earns Buy Rating from Analysts at HC WainwrightJune 10, 2025 | marketbeat.comDown 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)June 3, 2025 | zacks.comOmeros: On The Brink As It Awaits Its Fall PDUFA For A Potential BlockbusterMay 27, 2025 | seekingalpha.comOmeros: On The Brink As It Awaits Its Fall PDUFA For A Potential BlockbusterMay 27, 2025 | seekingalpha.comJulian Lucas on Hilton Als’s “The Islander”May 25, 2025 | newyorker.comNOmeros Corporation (NASDAQ:OMER) Q1 2025 Earnings Call TranscriptMay 17, 2025 | insidermonkey.comQ1 2025 Omeros Corp Earnings CallMay 17, 2025 | finance.yahoo.comOmeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...May 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom3 Cloud Software Leaders Positioned for AI UpsideBy Chris Markoch | July 10, 2025View 3 Cloud Software Leaders Positioned for AI UpsideBroadcom’s Big VMware Update: A Threat to Public Cloud Giants?By Leo Miller | June 28, 2025View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?GE Aerospace Turns Engines Into Long-Term ProfitsBy Jeffrey Neal Johnson | June 21, 2025View GE Aerospace Turns Engines Into Long-Term ProfitsNEOS, DSGN, OMER, and NBTX Company DescriptionsDesign Therapeutics NASDAQ:DSGN$4.04 -0.13 (-3.12%) Closing price 04:00 PM EasternExtended Trading$4.06 +0.01 (+0.37%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Nanobiotix NASDAQ:NBTX$5.36 +0.02 (+0.28%) Closing price 03:58 PM EasternExtended Trading$5.36 0.00 (0.00%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Neos Therapeutics NASDAQ:NEOSNeos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.Omeros NASDAQ:OMER$3.46 +0.08 (+2.37%) Closing price 04:00 PM EasternExtended Trading$3.45 -0.01 (-0.32%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
